8.6134
Ars Pharmaceuticals Inc Aktie (SPRY) Neueste Nachrichten
ARS Pharma (NASDAQ: SPRY) offers free virtual visit, $0 co-pay for neffy access - Stock Titan
105,000 Shares in ARS Pharmaceuticals, Inc. $SPRY Bought by Hussman Strategic Advisors Inc. - MarketBeat
Why ARS Pharmaceuticals Inc. stock could see breakout soonWeekly Profit Recap & Weekly Breakout Watchlists - newser.com
How ARS Pharmaceuticals Inc. stock benefits from strong dollar2025 Support & Resistance & Fast Gaining Stock Reports - newser.com
How ARS Pharmaceuticals Inc. stock trades during market volatilityTreasury Yields & Real-Time Volume Triggers - newser.com
Can ARS Pharmaceuticals Inc. hit a new high this monthJuly 2025 Fed Impact & Free Community Supported Trade Ideas - newser.com
Multi factor analysis applied to ARS Pharmaceuticals Inc.Weekly Profit Report & Daily Stock Momentum Reports - newser.com
UPDATE -- ARS Pharma to Present Real-World Data on Intranasal Epinephrine at 2025 American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific Meeting - The Manila Times
UPDATE -- ARS Pharma to Present Real-World Data on - GlobeNewswire
ARS Pharma (Nasdaq: SPRY) to present real-world neffy data: 1 late-breaking oral, 6 posters - Stock Titan
What drives ARS Pharmaceuticals Inc stock priceFlag and Pennant Patterns & Learn to Think Like a Long-Term Investor - earlytimes.in
Why ARS Pharmaceuticals Inc. stock could rally in 20252025 Geopolitical Influence & Consistent Profit Trade Alerts - newser.com
Will ARS Pharmaceuticals Inc. rebound enough to break evenJuly 2025 Short Interest & Expert Curated Trade Setup Alerts - newser.com
ARS Pharmaceuticals (NASDAQ: SPRY) to Host Q3 Results Webcast; Replay for 30 Days - Stock Titan
ARS Pharmaceuticals Announces Conference Call and Webcast for its Third Quarter 2025 Financial Results - Yahoo Finance
ARS Pharma Presents Late-Breaking Oral and Poster Sessions on Real-World Effectiveness of neffy® at ACAAI 2025 Annual Scientific Meeting - Quiver Quantitative
ARS Pharmaceuticals Inc. stock outlook for YEAR2025 Short Interest & Reliable Momentum Entry Alerts - newser.com
ARS Pharma (Nasdaq: SPRY) shares 9 of 10 anaphylaxis cases treated with single-dose neffy - Stock Titan
Custom strategy builders for tracking ARS Pharmaceuticals Inc.Weekly Gains Report & Free Daily Entry Point Trade Alerts - newser.com
Will ARS Pharmaceuticals Inc. stock maintain momentum in 2025Weekly Investment Recap & Technical Pattern Based Signals - newser.com
Trend analysis for ARS Pharmaceuticals Inc. this week2025 Investor Takeaways & Capital Efficiency Focused Strategies - newser.com
Reversal indicators forming on ARS Pharmaceuticals Inc. stockTrade Signal Summary & Expert Verified Stock Movement Alerts - newser.com
Applying chart zones and confluence areas to ARS Pharmaceuticals Inc.Weekly Gains Report & Weekly Market Pulse Alerts - newser.com
Why ARS Pharmaceuticals Inc. stock could outperform in 2025Market Sentiment Report & Short-Term High Return Strategies - newser.com
Is ARS Pharmaceuticals Inc. stock supported by innovation pipelineDividend Hike & Daily Volume Surge Trade Alerts - newser.com
Why ARS Pharmaceuticals Inc. stock is recommended by analystsTrade Volume Summary & Growth Focused Investment Plans - newser.com
ARS Pharmaceuticals Hits New 52-Week Low at $8.59 Amid Financial Struggles - Markets Mojo
Published on: 2025-11-02 04:08:25 - newser.com
How ARS Pharmaceuticals Inc. stock reacts to inflationary pressuresJuly 2025 Outlook & Precise Trade Entry Recommendations - newser.com
Published on: 2025-11-01 01:27:58 - newser.com
ARS Pharmaceuticals (NASDAQ:SPRY) Hits New 52-Week LowWhat's Next? - MarketBeat
How ARS Pharmaceuticals Inc. stock valuations compare to rivalsWeekly Stock Recap & Low Drawdown Investment Ideas - newser.com
Is ARS Pharmaceuticals Inc. a candidate for recovery playWeekly Stock Report & AI Forecasted Entry/Exit Points - newser.com
ARS Pharmaceuticals Hits New 52-Week Low at $8.90 Amid Financial Struggles - Markets Mojo
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):